Cellectis S.A. is a clinical-stage biopharmaceutical company that specializes in developing innovative immunotherapies for the treatment of various types of cancer. The company utilizes its proprietary gene editing platform to create CAR-T cell therapies that specifically target cancer cells while sparing healthy cells. With a robust pipeline of promising candidates, Cellectis is well-positioned to make a significant impact in the field of oncology.
